$20.34
3.35% yesterday
Nasdaq, Aug 12, 10:07 pm CET
ISIN
US14888U1016
Symbol
CPRX

Catalyst Pharmaceuticals, Inc. Stock price

$20.34
-1.28 5.92% 1M
-2.36 10.40% 6M
-0.53 2.54% YTD
+1.04 5.39% 1Y
+6.44 46.33% 3Y
+16.98 505.36% 5Y
+16.01 369.75% 10Y
+14.24 233.44% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+0.66 3.35%
ISIN
US14888U1016
Symbol
CPRX
Industry

Key metrics

Basic
Market capitalization
$2.4b
Enterprise Value
$1.8b
Net debt
positive
Cash
$652.8m
Shares outstanding
122.4m
Valuation (TTM | estimate)
P/E
11.9 | 13.2
P/S
4.3 | 4.2
EV/Sales
3.1 | 3.1
EV/FCF
6.4
P/B
2.8
Financial Health
Equity Ratio
85.5%
Return on Equity
22.5%
ROCE
28.3%
ROIC
60.1%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$558.5m | $572.2m
EBITDA
$280.8m | $234.0m
EBIT
$243.4m | $228.7m
Net Income
$208.7m | $182.3m
Free Cash Flow
$274.7m
Growth (TTM | estimate)
Revenue
28.5% | 16.4%
EBITDA
130.0% | 0.6%
EBIT
183.5% | 17.2%
Net Income
206.4% | 11.2%
Free Cash Flow
39.8%
Margin (TTM | estimate)
Gross
85.8%
EBITDA
50.3% | 40.9%
EBIT
43.6%
Net
37.4% | 31.9%
Free Cash Flow
49.2%
More
EPS
$1.7
FCF per Share
$2.2
Short interest
9.4%
Employees
181
Rev per Employee
$2.7m
Show more

Is Catalyst Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Catalyst Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Catalyst Pharmaceuticals, Inc. forecast:

13x Buy
93%
1x Hold
7%

Analyst Opinions

14 Analysts have issued a Catalyst Pharmaceuticals, Inc. forecast:

Buy
93%
Hold
7%

Financial data from Catalyst Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
559 559
29% 29%
100%
- Direct Costs 79 79
37% 37%
14%
479 479
27% 27%
86%
- Selling and Administrative Expenses 183 183
12% 12%
33%
- Research and Development Expense 15 15
83% 83%
3%
281 281
130% 130%
50%
- Depreciation and Amortization 37 37
3% 3%
7%
EBIT (Operating Income) EBIT 243 243
183% 183%
44%
Net Profit 209 209
206% 206%
37%

In millions USD.

Don't miss a Thing! We will send you all news about Catalyst Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Catalyst Pharmaceuticals, Inc. Stock News

Neutral
Seeking Alpha
5 days ago
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Jeffrey Del Carmen - Executive VP & Chief Commercial Officer Michael W. Kalb - Executive VP, Treasurer & CFO Richard John Daly - President, CEO & Director William T.
Neutral
GlobeNewsWire
6 days ago
Achieved Record Q2 2025 Total Revenues of $146.6 Million, an Increase of 19.4% Yo Y, Marking Another Quarter of Consecutive Growth Reported Record First Half 2025 Total Revenues of $288.0 Million, an Increase of 30.2% Over Prior Year Reaffirms Full-Year 2025 Total Revenue Guidance of $545 Million to $565 Million, Reflecting Broad-Based Growth and Sustained Demand FIRDAPSE® Q2 2025 Net Product R...
Neutral
GlobeNewsWire
7 days ago
CORAL GABLES, Fla., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced the National Comprehensive Cancer Network® (NCCN) Clinical Practice Guide...
More Catalyst Pharmaceuticals, Inc. News

Company Profile

Catalyst Pharmaceuticals is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

Head office United States
CEO Richard Daly
Employees 181
Founded 2002
Website catalystpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today